文献速递血栓与止血

血友病A抑制物即时检测纸基方法的开发与验证

A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients.
PubMed 文献 · J Thromb Haemost · 2026-04-20

本研究开发并验证了一种基于纸基条、全长重组FVIII和金纳米颗粒标记抗体的即时检测(POC)方法,用于诊断血友病A患者的FVIII抑制物。与Nijmegen改良Bethesda法相比,该POC检测的灵敏度为0.93、特异度为0.99、阳性预测值为0.94、阴性预测值为0.99、准确度为0.98。该检测仅需10分钟、成本约1–1.5美元、无需设备、仅需50 μL枸橼酸全血或血浆,且不受非中和抗体、残留FVIII、艾美赛珠单抗、狼疮抗凝物或肝素影响。

要点

  • POC检测诊断FVIII抑制物的灵敏度0.93、特异度0.99、准确度0.98。
  • 检测仅需10分钟、约1–1.5美元、50 μL枸橼酸全血或血浆,裸眼判读。
  • 不受非中和抗体、残留FVIII、艾美赛珠单抗、狼疮抗凝物或肝素干扰。

核心结论

  • 该POC检测有望作为资源有限环境下筛查FVIII抑制物的工具, turnaround time 10分钟,有助于及时临床决策。

研究设计与样本

  • 开发并验证一种纸基条格式的POC检测,使用全长重组FVIII和金纳米颗粒标记抗体。

主要发现

  • 与Nijmegen改良Bethesda法相比,诊断灵敏度0.93、特异度0.99、阳性预测值0.94、阴性预测值0.99、准确度0.98。
  • 检测快速(10分钟)、成本约1–1.5美元、无需设备(裸眼检测)、仅需50 μL枸橼酸全血或血浆。
  • 检测不受非中和抗体、残留FVIII、艾美赛珠单抗、狼疮抗凝物或肝素影响。

关键数值与推荐

  • 诊断灵敏度0.93、特异度0.99、阳性预测值0.94、阴性预测值0.99、准确度0.98(对比Nijmegen改良Bethesda法)。

临床怎么用

  • 可在资源有限、缺乏精密设备或技术专长的最低层级医疗系统中用于FVIII抑制物的及时筛查。
  • 10分钟出结果,有助于及时临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of neutralizing antibodies or inhibitors against exogenous factor (F)VIII represents a major adverse event in hemophilia A treatment. The conventional assay for the diagnosis of FVIII inhibitors is the Nijmegen-modified Bethesda assay. This test is time-consuming, resource-intensive, and cost-prohibitive. The test lacks sensitivity and shows wide variation across quality surveys. OBJECTIVES: To develop a rapid, cost-effective, functionally relevant, sensitive, and specific test for FVIII inhibitors. METHODS: We developed and validated a cost-effective, accurate, and equipment-free point-of-care (POC) test for FVIII inhibitors in a paper-strip format using full-length recombinant FVIII and gold nanoparticle-labeled antibodies. RESULTS: The diagnostic sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the FVIII inhibitor POC test were 0.93, 0.99, 0.94, 0.99, and 0.98, respectively, compared with the Nijmegen-modified Bethesda assay. The test was rapid (10 minutes), cost-effective (USD ≈$1-$1.5), equipment-free (naked-eye test), and required only a small volume (50 μL) of citrated whole blood or citrated plasma. The POC test was unaffected by nonneutralizing antibodies, residual FVIII, emicizumab, lupus anticoagulants, or heparin. CONCLUSION: The POC test shows promise as a valuable screening tool in resource-limited settings for timely diagnosis of FVIII inhibitors and can be applied even at the lowest tier of the health care system, where sophisticated equipment or technical expertise may not be available. With a turnaround time of 10 minutes, this POC test will be highly useful for timely clinical decision-making.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kharat S, Jivani F, Patil K, et al. A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients. J Thromb Haemost. 2026. PMID: 42019567. doi:10.1016/j.jtha.2026.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。